A new digital wound care module assists clinicians in selecting appropriate dressings and generating standardized treatment ...

MediWound Ltd. (NASDAQ: MDWD) Q3 2025 Earnings Call Transcript November 20, 2025 MediWound Ltd. beats earnings expectations.

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; ...

Researchers confirm that neuropathy and ischaemia are two main factors that result in diabetic foot ulcer with significant impairment of quality of life.

The wound healing devices market is largely propelled by the growing incidence of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure sores, along with a rise in surgical ...

Observed annually on the third Thursday of November each year, Worldwide Pressure Injury Prevention Day serves as a global ...

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx- in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid- Facility; Full Operational Capacity Expected by Year-End 2025 ...

Kure Care, a division of Veracor Group LLC, urges Medicare beneficiaries with chronic wounds to seek regenerative treatment before January 1, 2026 Medicare reimbursement changes. The company offers ...

Mediwound ( ($MDWD) ) has released its Q3 earnings. Here is a breakdown of the information Mediwound presented to its investors. MediWound Ltd., a ...

MediWound Ltd (MDWD) reports a 23% revenue increase and strategic advancements, despite facing operational and financial ...

Kure Care CEO Kenton Gray urges chronic wound patients to seek treatment immediately. Medicare changes effective January 1, ...

Vivex Biologics, Inc., a leading medical technology company, developing and delivering innovative allografts for ...